Literature DB >> 2459325

Desensitization of acetylcholine receptors in rat myotubes is enhanced by agents that elevate intracellular cAMP.

P Middleton1, L L Rubin, S M Schuetze.   

Abstract

Incubating skeletal muscle fibers with forskolin, an activator of adenylate cyclase, increases the rate at which nicotinic acetylcholine receptors (AChRs) desensitize when exposed to ACh. Several reports indicate that this is due to the phosphorylation of AChRs by cAMP-dependent protein kinase, but other studies suggest that forskolin interacts with AChRs directly and that second-messenger systems are not required. To help clarify this issue, we studied the effects of forskolin and several other drugs on AChR function in embryonic rat myotubes. AChR function was studied by recording ACh-induced membrane depolarizations and ACh-induced single-channel currents. Our results indicate that forskolin at low concentrations enhances AChR desensitization through the action of a second messenger, most likely cAMP. An analog of forskolin that is much less effective in activating adenylate cyclase (1,9-dideoxyforskolin) is also much less potent in enhancing desensitization. Forskolin at low concentrations does not alter single-channel conductance or mean channel open time. However, when used at concentrations above 20 microM, forskolin may also exert direct drug effects on AChRs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2459325      PMCID: PMC6569451     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  11 in total

1.  Changes in kinetics of acetylcholine receptor channels after initial expression in Xenopus myocyte culture.

Authors:  J Rohrbough; Y Kidokoro
Journal:  J Physiol       Date:  1990-06       Impact factor: 5.182

2.  Long-term desensitization of nicotinic acetylcholine receptors is regulated via protein kinase A-mediated phosphorylation.

Authors:  K Paradiso; P Brehm
Journal:  J Neurosci       Date:  1998-11-15       Impact factor: 6.167

3.  Properties of the nicotinic-receptor-activated current in adrenal chromaffin cells of the guinea-pig.

Authors:  M Inoue; H Kuriyama
Journal:  Pflugers Arch       Date:  1991-08       Impact factor: 3.657

4.  Enhancement by calcitonin gene-related peptide of non-contractile Ca2(+)-induced nicotinic receptor desensitization at the mouse neuromuscular junction.

Authors:  K Dezaki; I Kimura; H Tsuneki; M Kimura
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

5.  Effects of forskolin and analogues on nicotinic receptor-mediated sodium flux, voltage-dependent calcium flux, and voltage-dependent rubidium efflux in pheochromocytoma PC12 cells.

Authors:  Y Nishizawa; K B Seamon; J W Daly; R S Aronstam
Journal:  Cell Mol Neurobiol       Date:  1990-09       Impact factor: 5.046

6.  Developmental regulation of multiple nicotinic AChR channel subtypes in embryonic chick habenula neurons: contributions of both the alpha 2 and alpha 4 subunit genes.

Authors:  A B Brussaard; X Yang; J P Doyle; S Huck; L W Role
Journal:  Pflugers Arch       Date:  1994-11       Impact factor: 3.657

7.  Kinetics of desensitization and recovery from desensitization for human alpha4beta2-nicotinic acetylcholine receptors stably expressed in SH-EP1 cells.

Authors:  Kewei D Yu; Qiang Liu; Jie Wu; Ronald J Lukas
Journal:  Acta Pharmacol Sin       Date:  2009-06       Impact factor: 6.150

8.  Activation of protein kinase C potentiates postsynaptic acetylcholine response at developing neuromuscular synapses.

Authors:  W M Fu; J L Lin
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

9.  Additive effect of ADP and CGRP in modulation of the acetylcholine receptor channel in Xenopus embryonic myocytes.

Authors:  J C Liou; W M Fu
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

10.  Potentiation of acetylcholine responses in Xenopus embryonic muscle cells by dibutyryl cAMP.

Authors:  W M Fu
Journal:  Pflugers Arch       Date:  1993-12       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.